5:02 PM
 | 
May 27, 2010
 |  BC Extra  |  Company News

NICE backs Iressa for NSCLC

The U.K.'s NICE issued a final appraisal determination for Iressa gefitinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) only in patients with an EGFR...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >